10-Q: National Research Corporation Reports Second Quarter 2024 Results with Revenue Decline and Strategic Acquisition

National Research Corporation's second quarter 2024 results show a revenue decrease compared to the same period last year, alongside a strategic acquisition of Nobl, Inc.

Summary

• National Research Corporation, also known as NRC Health, reported a revenue of $35.02 million for the three months ended June 30, 2024, a decrease from $36.16 million in the same period of 2023.
• For the six months ended June 30, 2024, revenue was $70.33 million, down from $72.63 million in the first half of 2023.
• The company's operating income for the quarter was $8.87 million, compared to $9.37 million in the prior year.
• Net income for the quarter was $6.18 million, or $0.26 per diluted share, compared to $7.27 million, or $0.29 per diluted share, in the second quarter of 2023.
• The company's recurring contract value decreased to $138.43 million from $146.57 million year-over-year.
• NRC Health acquired Nobl, Inc. for $5.5 million in cash, with potential earn-out payments of up to $1.0 million based on performance through June 2026.
• The company amended its credit agreement, extending the maturity date of its line of credit to May 2027 and modifying the terms of its term loan and delayed draw term loan.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with a decline in key financial metrics and a strategic acquisition. The negative trends in revenue and recurring contract value are concerning, while the acquisition and credit agreement amendment offer some positive aspects. Overall, the sentiment is cautiously negative.

Positives

• The company's operating margin remained consistent at 25% for both the six-month periods ended June 30, 2024 and 2023.
• Cash provided by operating activities increased by 13% for the six months ended June 30, 2024, compared to the same period in 2023.
• The acquisition of Nobl, Inc. expands the company's service offerings in patient and employee experience.
• The amendment to the credit agreement provides extended financial flexibility with the line of credit maturity extended to May 2027.
• The company is investing in innovative AI solutions to support its clients.

Negatives

• Revenue decreased by 3% in both the three and six-month periods ended June 30, 2024, compared to the same periods in 2023.
• Recurring contract value declined by 6% year-over-year, indicating a potential challenge in maintaining and growing its client base.
• Net income decreased in both the three and six-month periods ended June 30, 2024, compared to the same periods in 2023.
• The company had a working capital deficit of $28.8 million as of June 30, 2024.
• Total other expenses increased due to lower interest income and higher interest expense from borrowings.

Risks

• The company faces risks related to non-renewal of client service contracts, reductions in services purchased, and increased price pressure.
• The company operates in a highly competitive market with new entrants, which could impact its market share and profitability.
• Economic downturns, global conflicts, and consolidation in the healthcare industry could adversely affect the company's operations and financial condition.
• The company's ability to attract and retain key personnel is crucial for its success.
• Cyber-attacks, security breaches, and failures in the company's information technology platform pose significant risks.
• The company's reliance on debt financing exposes it to interest rate fluctuations and potential covenant breaches.

Future Outlook

The company expects increased costs in future quarters to support investments in Human Understanding solutions and innovative AI solutions. They also anticipate increased selling, general, and administrative expenses due to new leadership positions and investments in product development and sales teams. Other expenses are expected to increase due to the August 2024 amendment to the credit agreement.

Management Comments

• The company's purpose is to humanize healthcare and support organizations in their understanding of each unique individual.
• The company believes that understanding the story is the key to unlocking the highest-quality and truly personalized care.
• The company's end-to-end solutions enable health care organizations to understand what matters most to each person they serve.
• The company is committed to Human Understanding to help leading healthcare systems get to know each person they serve not as point-in-time insights, but as an ongoing relationship.

Industry Context

The healthcare industry is increasingly focused on patient experience and engagement, making NRC Health's solutions highly relevant. The acquisition of Nobl, Inc. aligns with the trend of healthcare organizations seeking comprehensive solutions that integrate real-time feedback and data analytics. The company's cross-continuum positioning is also increasingly important as payment models drive healthcare providers and payers towards a more collaborative and integrated service model.

Comparison to Industry Standards

• While specific competitor data is not provided in the document, the decrease in recurring contract value suggests potential challenges in maintaining market share compared to industry benchmarks.
• The company's operating margin of 25% is within the range of typical software and services companies in the healthcare sector, but further analysis against specific competitors would be needed for a more detailed comparison.
• The company's focus on AI and data analytics aligns with industry trends, but the effectiveness of these investments will need to be monitored against competitors' offerings.
• The acquisition of Nobl, Inc. is a strategic move to enhance service offerings, which is a common strategy in the competitive healthcare technology market. Companies like Press Ganey and Qualtrics are also active in this space.

Stakeholder Impact

• Shareholders may be concerned about the decline in revenue and recurring contract value, but the acquisition and credit agreement amendment could be viewed positively.
• Employees may be affected by the company's workforce reduction and automation efforts, but the company is also investing in new leadership positions and product development.
• Customers may benefit from the company's expanded service offerings and innovative AI solutions.
• Creditors may be impacted by the company's increased debt levels and amended credit agreement.

Next Steps

• The company will finalize the accounting for the Nobl, Inc. acquisition by the end of the third quarter of 2024.
• The company will continue to invest in innovative AI solutions and product development.
• The company will monitor the impact of the amended credit agreement on its financial flexibility.
• The company will focus on growing its recurring contract value and retaining existing clients.

Key Dates

Keywords

healthcare analytics, patient experience, employee engagement, recurring contract value, subscription services, financial results, acquisition, credit agreement, Nobl Inc, AI solutions